STRATA Skin Sciences Q3 revenue down 6% to $8.9M; suspends FY 2023 guidance

STRATA Skin Sciences, Inc.

2023-Q3 EPS reported -$0.20 revenue$24,669,000

Total revenues $8.9M vs $9.4M in Q3 2022 (-6.0%); global recurring rev $5.3M vs $5.8M.
Net loss $1.1M ($0.03 loss per share) vs $1.0M loss in Q3 2022.
Non-GAAP EBITDA improved to $1.0M from $0.6M; gross margin fell to 56% from 62%.
Company suspends FY 2023 guidance following management change effective Oct 31, 2023.
Dr. Dolev Rafaeli named CEO and Vice-Chairman, effective October 31, 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

STRATA Skin Sciences, Inc. reported the third fiscal quarter ended September 30, 2023 results: revenue $8.9 million, net income Net loss for the third quarter of 2023 was $1.1 million, or a loss of $0.03 per basic and diluted common share, EPS $0.03 per basic and diluted common share.

Period: the third fiscal quarter ended September 30, 2023
Revenue: $8.9 million
Net income: Net loss for the third quarter of 2023 was $1.1 million, or a loss of $0.03 per basic and diluted common share
EPS: $0.03 per basic and diluted common share
Result: reported results

Exact text from the filing

conditions, today announced financial results for the third quarter ended September 30, 2023. Third Quarter 2023 and Recent Business Highlights: ● Total Revenues were $8.9 million compared to $9.4 million for the third quarter of 2022, a total decrease of 6.0%. ● Non-GAAP EBITDA improved to $1.0 million compared to $0.6 million for the third quarter of

View on SEC.gov

Browse all earnings releases →

STRATA Skin Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-053319

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.